Paul Hazen, MD
Dermatology · Westlake, OHNPI 1659352367
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,891 of the $33,486 with a category attached, or 65.4%. AbbVie accounts for 69.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $11,006 and has fallen 91.7% since, to $908 in 2025. Among dermatology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $145.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Novartis$7K
- UCB, Inc.$711
- Boehringer Ingelheim International GmbH$441
- Sun Pharmaceutical Industries Inc.$310
- Johnson & Johnson$259
- plus $2K from 23 others
Across 1 payment — averaging $2300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$2K
What the payments were for
- Consulting fees$5,05015%
- Speaking & faculty fees$21,89165%
- Travel & lodging$1,7065%
- Food & beverage$4,71414%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $23,248 |
| Novartis | 33 | $6,753 |
| UCB, Inc. | 24 | $711 |
| Boehringer Ingelheim International GmbH | 3 | $441 |
| Sun Pharmaceutical Industries Inc. | 16 | $310 |
| Johnson & Johnson | 18 | $259 |
| Boehringer Ingelheim | 11 | $253 |
| Lilly USA, LLC | 11 | $223 |
| Sanofi | 10 | $201 |
| Amgen | 9 | $169 |
| LEO Pharma Inc. | 6 | $157 |
| Regeneron Healthcare Solutions, Inc. | 5 | $122 |
| Pfizer | 4 | $74 |
| Merck | 5 | $70 |
| Bristol Myers Squibb | 3 | $68 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $62 |
| Incyte Corporation | 3 | $55 |
| Galderma Laboratories, L.p. | 3 | $51 |
| Mylan Institutional Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Mayne Pharma Commercial LLC | 2 | $29 |
| Organogenesis Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Biofrontera Inc. | 1 | $19 |
| Dermavant Sciences, Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,486 in reported general payments places this provider in the 90th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $141,604 |
| InflectraInfliximab-Dyyb | 13 | $42,586 |
| MitigareColchicine | 12 | $2,016 |
| Dapsone | 18 | $1,642 |
| Rifampin | 24 | $1,291 |
| Doxycycline Hyclate | 42 | $753 |
| Clindamycin Hcl | 22 | $553 |
| Minocycline Hcl | 21 | $409 |
| Clindamycin Phosphate | 11 | $335 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $324 |
| Triamcinolone Acetonide | 23 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInflectra | $74 | $42,58613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 460 dermatology providers in Ohio.
Other dermatology in Westlake
- Michael ReepWestlake$308K
- Richard AssafWestlake$16K
- Matthew ZirwasBexley$3.3M
- George DrewMarion$1.9M
- Rocco SerraoDayton$1.7M
- James LibeccoFairlawn$1.1M
- Pranav ShethWest Chester$978K
- Dawn MerrittAthens$844K
- Neil KormanCleveland$824K
- Joshua GrosshandlerWesterville$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.